Navigate this market better. Subscribe for FREE stock alerts and information.

Monday, September 29, 2014

CORRECTED-Valeant Pharmaceuticals' third-quarter sales to rise -filing, (NYSE: AGN), (NYSE: VRX), (TSE: VRX.TO)

Valeant Pharmaceuticals International Inc's sales are expected to rise 15 percent in the third quarter but will face a tougher fourth-quarter comparison to year-ago results, Allergan Inc said in a filing on Monday.Allergan, the maker of Botox anti-wrinkle injections, has criticized Valeant's acquisition-based business model as it attempts to fend off the drugmaker's $51 billion hostile bid.Valeant's third-quarter sales will reflect a weak year-ago period for contact lens maker Bausch & Lomb, which Valeant acquired for $8.7 billion in August 2013, according to the filing.The Canadian company did not give a specific fourth-quarter forecast but said last week that it expects continued strong double-digit same store organic growth in the fourth quarter. Valeant announced that it will report third-quarter earnings on Oct. 20.

Allergan, Inc. is a multi-specialty health care Company focused on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter products. Shares of AGN traded higher by 0.96% or $1.7/share to $179.70. In the past year, the shares have traded as low as $88.34 and as high as $181.94. On average, 1952900 shares of AGN exchange hands on a given day and today's volume is recorded at 2260112.

Valeant Pharmaceuticals International, Inc., formerly Biovail Corporation, is a multinational, specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products. Shares of VRX traded higher by 0.98% or $1.27/share to $130.26. In the past year, the shares have traded as low as $102.60 and as high as $153.10. On average, 2529350 shares of VRX exchange hands on a given day and today's volume is recorded at 2663223.

Valeant Pharmaceuticals International, Inc., formerly Biovail Corporation, is a multinational, specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products. Shares of VRX traded higher by 0.25% or $0.36/share to $144.67. In the past year, the shares have traded as low as $107.30 and as high as $170.45. On average, 398500 shares of VRX.TO exchange hands on a given day and today's volume is recorded at 616786.



Source